Dr. John Gribben, University of London, and Dr. Constantine Tam, Peter MacCallum Cancer Centre, join Patient Power Founder, Andrew Schorr, to discuss the current frontline treatment advances for CLL. Learn more about the results of the Resonate II trial, including survival advantages and durable control, as well as cumulative toxicity and cost.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo
Advertisement